Clinical Trial Update: Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) [Phase 2]

View source ↗

Summary

Phase 2 trial update for simtuzumab (GS-6624) in adults with primary sclerosing cholangitis (PSC) completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerosing Cholangitis

Drugs mentioned

• Simtuzumab (simtuzumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Primary Sclerosing Cholangitis (PSC) | Phase 2 | Status: COMPLETED | Results posted: 2019-10-22